Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

  • Xinyang Liu1, 2,
  • Shukui Qin3,
  • Zhichao Wang2,
  • Jianming Xu4,
  • Jianping Xiong5,
  • Yuxian Bai6,
  • Zhehai Wang7,
  • Yan Yang8,
  • Guoping Sun9,
  • Liwei Wang10,
  • Leizhen Zheng11,
  • Nong Xu12,
  • Ying Cheng13,
  • Weijian Guo14,
  • Hao Yu15,
  • Tianshu Liu2,
  • Pagona Lagiou1, 16Email author and
  • Jin Li17Email author
Journal of Hematology & Oncology201811:5

https://doi.org/10.1186/s13045-017-0545-5

Received: 22 November 2017

Accepted: 22 December 2017

Published: 9 January 2018

The original article was published in Journal of Hematology & Oncology 2017 10:153

Correction

The original article [1] contains two errors in Table 2:
  1. 1)

    The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.

     
  2. 2)

    The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.

     
Table 2

Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib

Clinical outcomes

With adverse events (n = 150)

Without adverse events (n = 119)

Unadjusted analysis

Multi-adjusted analysisa

HR/ORb (95% CI)

P valuec

HR/OR (95% CI)

P valued

Median overall survival (IQR), days

169 (96–255)

103 (58–201)

0.67 (0.51,0.88)

0.0039

0.64 (0.48,0.84)

0.001

Median progression-free survival (IQR), days

86.5 (57–150)

62 (41–121)

0.75 (0.58,0.98)

0.0309

0.69 (0.53,0.91)

0.007

Disease control rate, n (%)

82 (54.67)

39 (32.77)

2.47 (1.46,4.21)

< 0.001

2.67 (1.59,4.47)

< 0.001

Objective response rate, n (%)

11 (7.33)

6 (5.04)

1.49 (0.49.5.06)

0.443

1.42 (0.50,4.01)

0.505

Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment

HR hazard ratio, OR odds ratio, IQR interquartile range

aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS

bHR for overall survival and progression survival; OR for disease control rate and objective response rate

cP values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate

dP values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate

As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, USA
(2)
Fudan University Zhongshan Hospital, Shanghai, China
(3)
People’s Liberation Army Cancer Center, 81st Hospital of People’s Liberation Army, Beijing, China
(4)
Academy of Military Medical Sciences, 307th Hospital of PLA, Beijing, China
(5)
First Affiliated Hospital of Nanchang University, Nanchang, China
(6)
Harbin Medical University Cancer Hospital, Harbin, China
(7)
Shandong Cancer Hospital, Jinan, China
(8)
Gansu Cancer Hospital, Lanzhou, China
(9)
First Affiliated Hospital of Anhui Medical University, Hefei, China
(10)
Shanghai First People’s Hospital, Shanghai, China
(11)
XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China
(12)
First Affiliated Hospital of Zhejiang University, Hangzhou, China
(13)
Jilin Provincial Cancer Hospital, Changchun, China
(14)
Fudan University Shanghai Cancer Center, Shanghai, China
(15)
Nanjing Medical University, Nanjing, China
(16)
Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
(17)
Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

Reference

  1. Liu X, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement